Navigation Links
FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
Date:2/17/2011

SILVER SPRING, Md., Feb. 17, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with congenital Factor XIII deficiency don't make enough Factor XIII, a substance that circulates in the blood and is important for normal clotting. Without treatment, people with the condition are at risk for life-threatening bleeding.

Congenital Factor XIII deficiency is rare and affects 1 out of every 3 million to 5 million people in the United States. The deficiency may lead to soft tissue bruising, mucosal bleeding and fatal intracranial bleeding. Newborns with Factor XIII deficiency may have umbilical cord bleeding.

"This product helps fill an important need," said Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research.

Corifact received orphan-drug designation by the FDA because it is intended for use in a rare disease or condition. It was approved for marketing under the FDA's accelerated approval regulations that require an on-going study to demonstrate that patients actually receive the clinical benefit predicted by the data obtained so far.

The FDA approved Corifact based on results of a clinical study of 14 people, including children, with congenital Factor XIII deficiency. The most common side effects observed were hypersensitivity reactions (allergy, rash, pruritus, and erythema), chills, fever, arthralgia, headache, elevated thrombin-antithrombin levels, and an increase in liver (hepatic) enzymes.

Corifact is made from the pooled plasma of healthy donors. People receiving Corifact may develop antibodies against Factor XIII that may make the product ineffective. It potentially can cause adverse
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves First 3-D Mammography Imaging System
2. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
3. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
4. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
5. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
6. FDA Approves Viibryd to Treat Major Depressive Disorder
7. FDA Approves Head Lice Treatment for Children and Adults
8. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
9. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
10. FDA Approves New Dosage Strength for INTELENCE®
11. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. ... conducted in Melbourne, Australia ... the potential treatment of paroxysmal supraventricular tachycardia (PSVT).  ... MSP-2017 was well tolerated at single doses up ... safety profile, desirable PK properties including rapid onset, ...
(Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
(Date:11/24/2014)... , Nov. 24, 2014  Surgical Theater, LLC, announced ... November 24 th opening of Europe,s ... Neurologico Nazionale "C. Besta." The SuRgical Planner (SRP) and ... at the event for their 3D navigation and augmented ... Joshua Bederson , Professor and Chair, Department of Neurosurgery ...
Breaking Medicine Technology:Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3Relmada Therapeutics To Present At LD MICRO Conference 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... Inc. (Nasdaq: EFJI ), a leading provider of secure ... ended September 30, 2009. Revenues were $24.4 million, gross ... $(0.06) per diluted share, for the three months ended September ... and contract awards, the third quarter revenue results were not ...
... A new treatment for autism appears to normalize ... MD, FAACAP, BCIA-EEG. , In addition to ... "u" EEG pattern reflecting impaired brain function, particularly in ... speech and bonding. , However, Quantitative ...
Cached Medicine Technology:EF Johnson Technologies Announces Third Quarter Results 2EF Johnson Technologies Announces Third Quarter Results 3EF Johnson Technologies Announces Third Quarter Results 4EF Johnson Technologies Announces Third Quarter Results 5EF Johnson Technologies Announces Third Quarter Results 6EF Johnson Technologies Announces Third Quarter Results 7EF Johnson Technologies Announces Third Quarter Results 8New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3
(Date:11/24/2014)... York (PRWEB) November 24, 2014 Gersowitz Libo ... that it has received national Tier recognition in the 2015 ... Achieving a tiered ranking signals a unique combination of quality ... very proud to receive this honor and especially grateful to ... this important honor and ranking possible,” said Jeff S. Korek, ...
(Date:11/24/2014)... Pittsburgh, PA (PRWEB) November 24, 2014 ... as he was trying to cross the street in ... "The driver never saw him. I came up with ... easily visible at night." , He developed the Safety ... night or in low-lighting conditions. The device ensures that ...
(Date:11/23/2014)... November 24, 2014 iFitDress.com, a well-known wedding ... black evening gowns . They are now offered at ... offer will last from now to Dec. 15. The main ... , All the company’s high quality items are ideal options ... a large sum of money. All its new mint cocktail ...
(Date:11/23/2014)... The report, “Market Snapshot: Aesthetic Lasers ... Asia-Pacific” provides quantitative analysis of the three aesthetic ... body contouring devices, non-invasive body contouring devices and ... data by revenue and volume over the 2006 ... South Korea, Australia and India. It uses data ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water tank ... an 8 year warranty on its selected hot water tanks. ... due to the impending winter season, it was important for ... service that the company provides. As a result, Pro Ace ... and Bradford hot water tanks. , “Every installer who ...
Breaking Medicine News(10 mins):Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... School of Medicine have discovered that drinking just 500ml ... pressure. The study, published online today in the American ... the treatment of cardiovascular disease. , Lead by Professor ... Barts and The London School of Medicine, and Professor ...
... spending on medical research in Europe should be doubled ... welfare for Europes citizens and to nurture a thriving ... between European institutions in medical research and improved career ... the main recommendations of the European Medical Research Councils ...
... workforce raises serious,concerns, WASHINGTON, Feb. 5 ... strong objections to President,Bush,s FY2009 budget for both ... the FY 2009 budget reflects some poor choices ... setting a hazardous course for,the future., "The ...
... a clue leading researchers at Washington University School of ... approach for Niemann-Pick disease, a rare, deadly neurodegenerative disorder. ... disease, the researchers suggest that chemical compounds could potentially ... machinery. And they believe the approach also could be ...
... ... Xactly Incent on-demand solution, SAN JOSE, Calif., ... performance management, today announced that Volcano,Corporation (Nasdaq: VOLC ... diagnosis and treatment of vascular and structural heart,diseases, has ...
... ATLANTA, Feb. 5 Ingenious Med, leaders in ... practice management,announces record sales, product deployments, partnerships, and ... 2007 sales increased by,81% over 2006. This increase ... a,dramatic increase in IM,s overall profitability., In ...
Cached Medicine News:Health News:Research shows a daily does of beetroot juice can beat high blood pressure 2Health News:Collaboration needed for strengthening medical research in Europe 2Health News:Association of Academic Health Centers Faults Bush's FY 2009 Budget 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 2Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 3Health News:Ingenious Med Reports Record Sales and Client Expansions in 2007 2
... launched the first generation HPLC system for ... a new level of automation to HPLC ... diabetes testing in Japan. Now in the ... G7 offers advanced automation; stable HbA1c results ...
... complete hematology automation to maximize workflow efficiency ... provides the flexibility to meet your laboratory ... module, one Load module, and one Unload ... basic system will incorporate a minimum of ...
... The STart benchtop coagulation ... of electro-mechanical clot detection. This ... icteric or other optically dense ... offers programmable and preprogrammed assays ...
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
Medicine Products: